2. One-Page Executive Summary (Text pre PDF prílohu EN

EXECUTIVE SUMMARY: STRATEGIC R&D & CO-PATENTING PROPOSAL

Project: Bio-Active Picea abies Phyto-Lipid Delivery Platform for Advanced Trichology & Dermocosmetics

Entity: Dr.FYTO® (Registered Trademark Pending/Active; Central Europe – 48°N)

Partnership Scope: Joint IP / Co-Patenting, Clinical Validation & Commercial Market Launch

1. The Market & Formulation Gap

Topical scalp and hair-density formulations face two primary limitations: poor transfollicular bioavailability of water-based botanical tonics and reliance on synthetic penetration enhancers or preservatives. Conversely, pure plant oils remain on the epidermal surface due to high triglyceride molecular weight and fail to extract water-soluble phenolic and organic acid fractions from coniferous raw materials.

2. The Dr.FYTO® Innovation

Dr.FYTO® has established a proprietary phytochemical selection and dual-phase cold-extraction protocol utilizing Norway spruce (Picea abies) harvested at the 48th parallel.

  • Seasonal Metabolite Standardization: Based on longitudinal profiling of Picea abies needles and spring shoots, raw material harvesting is strictly timed to peak secondary metabolite biosynthesis (late autumn accumulation and early spring pre-budding/budding windows), maximizing key bioactive markers:

    • Shikimic Acid (up to ~94.7 mg/g): Gentle keratoregulation, follicular orifice clearing, and microbiome balance (Malassezia control).

    • 4-Hydroxyacetophenone / Piceol (up to ~21.5 mg/g): Potent lipid peroxidation inhibitor protecting sebum squalene from oxidative stress, providing natural self-preserving stability.

    • Pinitol & Myo-Inositol (up to ~41.5 mg/g & 7.8 mg/g): Cellular osmoprotectants supporting local insulin/IGF-1 signaling pathways essential for the anagen hair phase.

    • (+)-Catechin & Proline: Antioxidant protection of dermal papilla cells, mild 5-alpha-reductase modulation, and support of perifollicular extracellular matrix integrity.

    • Monoterpenes & Sabinenes: Natural lipophilic penetration enhancers stimulating local microcirculation.

  • Anhydrous Reverse-Micelle Carrier System: A water-free, preservative-free matrix combining low-viscosity C8/C10 medium-chain triglycerides, phytosterol-rich Cucurbita pepo seed oil (beta-sitosterol), and non-GMO phospholipids (lecithin) to transport both lipophilic and amphiphilic fractions deep into the pilosebaceous unit.

3. Intellectual Property & Current Status

  • Brand Protection: The Dr.FYTO® trademark is officially filed and currently undergoing substantive examination.

  • R&D Readiness: Lab-scale prototypes, seasonal phytochemical datasets, and cold-extraction SOPs are established and ready for pilot scale-up and analytical standardization (HPLC/GC-MS).

  • Patentability: Novel combination of seasonally standardized Picea abies dual-fraction extraction integrated into an anhydrous phospholipid-MCT transfollicular carrier.

4. Proposed Partnership Models

Dr.FYTO® offers its proprietary phytochemical research, seasonal raw material sourcing protocol, and core formulation IP to a strategic industry leader under one of the following structures:

  1. Co-Development & Joint Patent Ownership: Shared R&D investment for clinical/instrumental efficacy testing, joint European/PCT patent filing, and co-branded product launch.

  2. Exclusive / Regional Licensing: Partnering with an established manufacturer/distributor for GMP scale-up, regulatory compliance (EU 1223/2009), and international commercialization.